Akcea Therapeutics obtains FDA Orphan Medication Designation for volanesorsen Akcea Therapeutics.

Akcea Therapeutics obtains FDA Orphan Medication Designation for volanesorsen Akcea Therapeutics, a wholly-owned subsidiary of Isis Pharmaceuticals, Inc. , announced today that the U.S. Food and Drug Administration offers granted Orphan Drug Designation to volanesorsen for the treatment of individuals with Familial Chylomicronemia Syndrome . FCS is certainly a rare genetic disease seen as a extremely high triglyceride levels and threat of pancreatitis.This plan effectively sets helping goals for the Association, along with detailed objectives for the current year, and broader goals for the next four years. Molecular pathology can be on its way to getting central to the practice of medicine, as molecular diagnostics proceeds to guide more accurate and personalized remedies, said Strategic Planning Implementation Committee Chair Dr. Karen Mann. AMP intends to make use of its influence and the knowledge of its people to provide education and promote policies that will enhance patient care.